Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer

Perifosine and ABT-737 synergistically inhibit lung cancer cells in vitro and in vivo

(2016) Jie Shen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective

(2016) Joseph Ciccolini et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Surgical and molecular pathology of pancreatic neoplasms

(2016) Wenzel M. Hackeng et al.   Diagnostic Pathology

Pleiotropic effects of antitumour alkylphospholipids on cholesterol transport and metabolism

(2016) Pablo Ríos-Marco et al.   EXPERIMENTAL CELL RESEARCH

Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

(2016) Patricia Mucci LoRusso   JOURNAL OF CLINICAL ONCOLOGY

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma

(2016) Matthew H. Wong et al.   NEOPLASIA

Salicylketoximes That Target Glucose Transporter 1 Restrict Energy Supply to Lung Cancer Cells

(2015) Carlotta Granchi et al.   ChemMedChem

Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma

(2015) Hideki Makinoshima et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2

(2015) H. P. Soares et al.   MOLECULAR CANCER THERAPEUTICS

PIM kinase (and Akt) biology and signaling in tumors

(2015) Noel A. Warfel et al.   PHARMACOLOGY & THERAPEUTICS

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

(2015) Anneleen Daemen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Unraveling the complexity of autophagy: Potential therapeutic applications in Pancreatic Ductal Adenocarcinoma

(2015) Valentina E. Gómez et al.   SEMINARS IN CANCER BIOLOGY

A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice

(2015) Ramaswamy Sharma et al.   Oncotarget

Perifosine as a potential novel anti-telomerase therapy

(2015) Brody Holohan et al.   Oncotarget

Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy

(2015) Hayato Fujita et al.   NEOPLASIA

Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer

(2015) Elena Galvani et al.   NEOPLASIA

Current View on the Mechanism of Action of Perifosine in Cancer

(2014) Joachim Fensterle et al.   Anti-Cancer Agents in Medicinal Chemistry

An update on therapeutic opportunities offered by cancer glycolytic metabolism

(2014) Carlotta Granchi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Perifosine inhibits S6K1–Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency

(2014) Ying Xin et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

AKT1 and SELP Polymorphisms Predict the Risk of Developing Cachexia in Pancreatic Cancer Patients

(2014) Abolfazl Avan et al.   PLoS One

Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma

(2014) C D Hudson et al.   Cell Death & Disease

Kras as a key oncogene and therapeutic target in pancreatic cancer

(2014) Meredith A. Collins et al.   Frontiers in Physiology

Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells

(2013) Tiziano Tuccinardi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing

(2013) Paola Longati et al.   BMC CANCER

AEG-1 Is a Target of Perifosine and Is Over-Expressed in Gastric Dysplasia and Cancers

(2013) Wenbin Huang et al.   DIGESTIVE DISEASES AND SCIENCES

Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations

(2012) Maha Elnaggar et al.   CURRENT PHARMACEUTICAL DESIGN

Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer

(2012) Amir Avan et al.   CURRENT PHARMACEUTICAL DESIGN

Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms

(2012) Kathrin Zitzmann et al.   ENDOCRINE-RELATED CANCER

Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways bothin vivoandin vitro

(2012) Min-Bin Chen et al.   INTERNATIONAL JOURNAL OF CANCER

Progesterone and DNA Damage Encourage Uterine Cell Proliferation and Decidualization through Up-regulating Ribonucleotide Reductase 2 Expression during Early Pregnancy in Mice

(2012) Wei Lei et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells

(2012) A. Avan et al.   MOLECULAR CANCER THERAPEUTICS

Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma

(2012) Giulia Pinton et al.   PLoS One

Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: More than just AKT inhibition

(2011) Hui Sun et al.   CANCER LETTERS

Akt signalling in health and disease

(2011) Ingeborg Hers et al.   CELLULAR SIGNALLING

Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis

(2011) N. B. Jamieson et al.   CLINICAL CANCER RESEARCH

An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer

(2011) Edward Chu   Clinical Colorectal Cancer

Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K—mTOR pathway in pancreatic adenocarcinoma

(2011) Olga K. Mirzoeva et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression

(2011) M-T Lau et al.   ONCOGENE

The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo

(2011) Yuanhong Gao et al.   Radiation Oncology

MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

(2010) Elisa Giovannetti et al.   CANCER RESEARCH

Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation

(2010) Hong-rong Fei et al.   CYTOTECHNOLOGY

203 Perifosine in combination with antimetabolites induces synergistic effects on cytotoxicity and apoptosis in human colon, multiple myeloma, breast, renal, and liver tumor cell lines

(2010) B. Aicher et al.   EJC SUPPLEMENTS

Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma

(2010) Adam D. Toll et al.   HUMAN PATHOLOGY

In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines

(2010) Martin Schmidt-Hieber et al.   INVESTIGATIONAL NEW DRUGS

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Activation of the PI3K/Akt Pathway Mediates Bone Morphogenetic Protein 2-Induced Invasion of Pancreatic Cancer Cells Panc-1

(2010) Xiong Chen et al.   PATHOLOGY & ONCOLOGY RESEARCH

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Perifosine: Update on a novel Akt inhibitor

(2009) Joell J. Gills et al.   Current Oncology Reports

Inhibition of Glutathione and Thioredoxin Metabolism Enhances Sensitivity to Perifosine in Head and Neck Cancer Cells

(2009) Andrean L. Simons et al.   Journal of Oncology

The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications

(2008) Amancio Carnero et al.   CURRENT CANCER DRUG TARGETS

IGF-1 Mediates PTEN Suppression and Enhances Cell Invasion and Proliferation via Activation of the IGF-1/PI3K/Akt Signaling Pathway in Pancreatic Cancer Cells

(2008) Jiachi Ma et al.   JOURNAL OF SURGICAL RESEARCH

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE